SARS-CoV-2

Chapter 2 Molecular Epidemiology of SARS-CoV-2 by Sequencing

Chapter 3 Advanced Genetic Methodologies in Tracking Evolution and Spread of SARS-CoV-2

Chapter 4 Antigen-Based Point of Care Testing (POCT) for Diagnosing SARS-CoV-2: Assessing Performance

Chapter 5 Diagnostic Method for COVID-19 Using Sugar Chain-Immobilized Nanoparticles and Saliva Specimens

Chapter 6 Detection and Quantification of SARS-CoV-2 by Real-Time RT-PCR Assay

Chapter 7 Immunofluorescent Antibody Techniques in the Diagnosis of SARS-CoV-2 Infection in Humans

Chapter 8 Propagation and Quantification of SARS-CoV-2

Chapter 9 Quantification of Infectious SARS-CoV-2 by the 50% Tissue Culture Infectious Dose Endpoint Dilution Assay

Chapter 10 One-Step Reverse Transcription Droplet Digital PCR Protocols for SARS-CoV-2 Detection and Quantification

Chapter 11 Profiling SARS-CoV-2 Infection by High-Throughput Shotgun Proteomics.

Chapter 12 Detection of SARS-CoV-2 by Mass Spectrometry

Chapter 13 Bioinformatics-Based Approaches to Study Virus-Host Interactions During SARS-CoV-2 Infection

Chapter 14 Human Nasal Epithelial Cells (hNECs ) Generated by Air-Liquid Interface (ALI) Culture as a Model System for Studying the Pathogenesis of SARS-CoV-2

Chapter 15 Animal Models of COVID-19: Nonhuman Primates

Chapter 16 Animal Models of COVID-19: Transgenic Mouse Model

Chapter 17 Immunohistochemical Detection of SARS-CoV-2 Antigens by Single and Multiple Immunohistochemistry

Chapter 18 Measuring Neutralizing Antibodies to SARS-CoV-2 Using Lentiviral Spike-Pseudoviruses

Chapter 19 Antiviral Strategies Against SARS-CoV-2: A Systems Biology Approach

Chapter 20 Neutralization Assay for SARS-CoV-2 Infection: Plaque Reduction Neutralization Test

Chapter 21 Pseudovirus-Based Assays for the Measurement of Antibody-Mediated Neutralization of SARS-CoV-2

Chapter 22 Cytopathic Effect (CPE )-Based Drug Screening Assay for SARS-CoV-2

Chapter 23 Strengthening Biorisk Management in Research Laboratories with Security-Sensitive Biological Agents Like SARS-CoV-2

Chapter 24 Biorisk Management for SARS-CoV-2 Research in a Biosafety Level-3 Core Facility

Chapter 25 Methods of SARS-CoV-2 Inactivation